The clinical backdrop explains why the innovation matters. Pancreatic ductal adenocarcinoma, the most common and most lethal form of pancreatic cancer, has seen its five-year overall survival improve from roughly 4 percent to 13 percent over recent decades, according to data cited in the report. Yet the prognosis remains poor, and typical presentations include weight loss, jaundice, abdominal pain, new or worsening diabetes, and steatorrhea, the fatty stools that signal impaired digestion. Tumors of the pancreatic head sit in a crowded anatomical neighborhood, wrapped around the portomesenteric venous confluence where the splenic and superior mesenteric veins merge into the portal vein. As the tumor grows, it can compress or invade these vessels, producing portal hypertension, fluid accumulation in the abdomen known as ascites, and swelling of the bowel wall that interferes with nutrition. Under European Society for Medical Oncology guidelines, contrast-enhanced computed tomography is the mainstay of diagnosis, mapping tumor size, vascular involvement, and metastatic spread, while biopsy is indicated before chemotherapy, with endoscopic ultrasound-guided fine-needle biopsy preferred over CT-guided approaches.

The patient in the report arrived with a four-month history of weight loss, mild steatorrhoea, and newly developed ascites. Imaging revealed a mass in the pancreatic head that encased both the superior mesenteric vein and the superior mesenteric artery, obstructed the portomesenteric venous confluence, and had spawned a network of venous collaterals alongside thickening of the bowel wall, particularly the duodenum. Apposing thrombus, or clot, was also present within the affected veins. He was judged ineligible for surgery, making a tissue diagnosis essential before palliative chemotherapy could begin. The first endoscopic ultrasound-guided biopsy attempt had to be abandoned because interposed collateral vessels blocked a safe needle path. A second attempt returned tissue that showed only signs of chronic pancreatitis, an inconclusive result that left the team without proof of malignancy and the patient without access to cancer treatment.

At this point the multidisciplinary team chose a dual-purpose intervention. To relieve the ascites and bowel oedema, they planned a transjugular portosystemic shunt with portal vein recanalization, an approach abbreviated PVR-TIPS. In a standard TIPS procedure, a track is created through the liver connecting the hepatic vein to the portal vein, shunting blood to decompress the portal system. Here, the team extended the concept: after creating the shunt under fluoroscopic guidance, they passed catheters and guidewires through the blocked portomesenteric venous confluence and advanced them into the superior mesenteric vein, reopening the obstructed venous highway from within. This recanalization simultaneously created a working channel that led directly past the tumor-bearing portion of the pancreatic head.

What followed was the technically novel step. Because there was still no histological proof of cancer, the team decided to sample the tumor through the vein they had just reopened. An 8 French gastroscope biopsy forceps, an instrument normally used inside the stomach, was pushed under fluoroscopic guidance through the 10 French TIPS sheath and advanced into the tumor-bearing segment of the pancreatic head. Three tissue samples were obtained from inside the vessel. The interventional sequence was then completed with the placement of a 12-millimeter bare metal stent across the externally compressed venous segment, restoring flow through the portomesenteric confluence. The clinical response was rapid: bowel oedema resolved within hours, ascites decreased markedly within four weeks, and histology confirmed pancreatic ductal adenocarcinoma. Palliative chemotherapy was initiated just one week after the procedure.

The report situates this case within a growing but still limited literature on venous decompression in pancreatic cancer. Transhepatic portomesenteric venous stenting is already an established palliative treatment for locally advanced disease. In the largest published series, covering 129 patients of whom 119 had pancreatic cancer, technical success reached 97 percent with only four adverse events, and at 20 months of follow-up primary stent patency was 80 percent, with symptom relief in most patients. A separate series of 40 pancreatic cancer patients treated with direct percutaneous transhepatic portomesenteric venous stenting showed that the approach can do more than relieve symptoms: it enabled patients with tumor thrombus in the portal vein to receive chemotherapy, and 15 of the 40 went on to undergo the Whipple procedure, the complex surgical removal of the pancreatic head, without vascular resection.

Biopsy through blood vessels, by contrast, has a narrower track record. Non-targeted transvenous biopsies are routine for diffuse liver and kidney disease, but targeted transvenous sampling of specific lesions remains rare. Where it has been used, operators typically combine fluoroscopy with intravascular ultrasound for image guidance, and studies suggest the technique is valuable precisely for targets that lack a safe percutaneous window, the corridor of tissue a needle must cross to reach a lesion without injuring vessels or organs. Previous intraportal approaches have been percutaneous rather than transjugular: one recent report described a percutaneous transhepatic portal access using gastroscope biopsy forceps to biopsy portal vein invasion by a pancreatic neuroendocrine tumor, and a similar transhepatic route has been used in hepatocellular carcinoma with tumor thrombus. A transbiliary route, passing instruments through the bile ducts, has also been described for sampling inaccessible pancreatic head masses, though it is equally uncommon.

The transjugular route described in the new report offers distinct advantages. Because the shunt and stenting were performed anyway for palliative decompression, the biopsy added no separate access route, allowing venous decompression and histological confirmation to be accomplished in one sitting. The authors also argue that an endovascular transportal approach may reduce the inherent bleeding risk compared with percutaneous or endoscopic ultrasound-guided biopsy, in the same way that transjugular liver and kidney biopsies are favored in coagulopathic patients, since any bleeding occurs into the vessel itself rather than into the peritoneal cavity. Nevertheless, the technique is not without hazards: vessel injury remains a concern, and adjunct imaging such as cone-beam computed tomography is recommended to minimize damage to non-target structures and to improve sample quality. The single-case nature of the evidence means broader safety and efficacy data will be needed before the approach enters routine practice.

Even so, the case signals a meaningful expansion of the interventional toolkit for pancreatic cancer, a disease in which the window for effective treatment is often agonizingly narrow. For patients whose tumors are wrapped in collateral vessels, whose clot or anatomy blocks standard needle paths, or whose earlier biopsies returned falsely reassuring inflammation, the ability to combine shunt creation, vein recanalization, stenting, and tumor sampling through a single transjugular access could shorten the path from obstruction to diagnosis to chemotherapy. The report’s conclusion is measured but clear: endovascular transportal biopsy is a feasible method for obtaining histopathological diagnosis in pancreatic head tumors, even after failed endoscopic ultrasound-guided biopsy, and it can be seamlessly combined with other interventional measures such as portal vein recanalization and stenting. As interventional oncology continues to blur the line between diagnosis and treatment, this vein-borne route to one of medicine’s hardest-to-reach tumors may find a growing role.

Subject of Research: Endovascular transportal biopsy of pancreatic head tumors via the portal vein prior to stenting

Article Title: Transportal endovascular biopsy prior to portal vein stenting in pancreatic cancer

Article References: Mahnken, A. H. (2026). Transportal endovascular biopsy prior to portal vein stenting in pancreatic cancer. CVIR Oncology, 2(1), Article 12. https://doi.org/10.1007/s44343-026-00046-2

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00046-2

Keywords: pancreatic cancer, endovascular biopsy, portal vein stenting, transjugular portosystemic shunt, interventional radiology, pancreatic ductal adenocarcinoma, portal vein recanalization, endoscopic ultrasound, ascites, venous decompression, biopsy techniques, palliative care

The team previously developed “Panregza,” a test that combines peripheral whole-blood gene expression patterns with the serum tumor marker CA19-9. While Panregza has shown utility in later-stage disease, its performance in stage 0–Ⅰ cancers—where tumor burden is minimal—had not been established.

In the current pilot case–control study, the researchers analyzed whole-blood mRNA expression using a panel of 56 gene probes. They evaluated stage 0–Ⅰ pancreatic cancer samples from 10 patients (about 4% of a larger cohort) and compared them with 104 healthy individuals. Diagnostic performance was assessed for (1) gene expression alone, (2) CA19-9 alone, and (3) the combined Panregza system.

The blood gene expression method identified 9 of 10 early-stage cases, corresponding to 90% sensitivity. By contrast, CA19-9 detected only 1 of 10 cases, or 10% sensitivity, highlighting the limitation of relying on tumor marker levels for early disease.

When CA19-9 was combined with the gene expression readout, the Panregza system achieved 60% sensitivity and 93.3% specificity. Together, these results suggest that peripheral whole-blood transcriptional signatures carry clinically meaningful information even when CA19-9 is normal.

Importantly, the findings support a biological model in which pancreatic cancer-associated signaling alters gene expression in immune and other blood cell populations. Because these changes can occur before substantial tumor growth, they may enable detection that is not dependent on tumor volume.

The study also emphasizes the clinical significance of early diagnosis. At Kanazawa University Hospital’s Innovative Research and Development Center for Pancreatic Cancer, reported five-year survival rates are 100% for stage 0 and 74.4% for stage Ⅰ, reflecting the impact of catching disease early.

Overall, the work provides viral-science-news momentum for whole-blood mRNA diagnostics in pancreatic cancer and strengthens the case for further validation toward scalable screening.

Subject of Research: Whole-blood mRNA expression diagnostic system for early-stage pancreatic ductal adenocarcinoma (Panregza)

Article Title: Pilot validation of a whole-blood mRNA expression-based diagnostic system for early-stage pancreatic ductal adenocarcinoma: a single-center case–control diagnostic accuracy study

News Publication Date:

Web References: https://doi.org/10.1038/s41598-026-58684-8

References: 10.1038/s41598-026-58684-8

Image Credits: © Kanazawa University

Keywords: pancreatic cancer; early detection; whole-blood mRNA; gene expression; CA19-9; diagnostic accuracy; biomarker; Panregza; sensitivity; specificity; immune-associated transcriptional signatures

Pancreatic ductal adenocarcinoma remains one of the deadliest cancers, largely because it is customarily diagnosed at an advanced stage when therapeutic interventions offer minimal benefit. The aggressive nature of PDAC combined with its clinical silence contributes to dismal survival statistics, with many cases identified only after metastasis. Traditional computed tomography (CT) scans and clinical evaluations, despite their utility in many oncologic contexts, often fail to reveal the subtle microarchitectural tissue changes that herald the earliest cancerous transformations within the pancreas. This has fostered an urgent need for novel detection modalities capable of revealing these invisible early signs.

Addressing this critical gap, the REDMOD framework harnesses the power of radiomics—the extraction and analysis of complex quantitative features from medical images—combined with automated pancreas segmentation. This segmentation enables precise delineation of the pancreatic borders from surrounding tissues without manual oversight, mitigating risks associated with human error and variability. Such technical sophistication ensures that the AI examines consistent regions with high fidelity across diverse imaging datasets, a necessity for reliable early detection in a real-world clinical context.

To evaluate its clinical validity, the AI was retrospectively applied to abdominal CT scans from 219 patients initially deemed disease-free by radiologists but who were subsequently diagnosed with PDAC. These scans spanned time intervals extending up to three years prior to official diagnosis. Impressively, REDMOD identified pre-clinical malignant signatures an average of 475 days—approximately 15 months—before the clinical diagnosis was made. Notably, nearly two-thirds of these cancers were localized to the pancreatic head, an area notoriously challenging to assess. This discovery underscores a significant temporal window during which early intervention could substantially alter patient outcomes.

Comparison with a large control group comprising 1,243 age-, sex-, and scan-date matched individuals who remained PDAC-free for over three years highlighted REDMOD’s specificity. The model accurately recognized over 81% of cases as negative for cancer in an independent multicenter cohort and demonstrated 87.5% accuracy in a publicly available NIH dataset. Such high specificity is crucial in minimizing false positives that can lead to anxiety and unnecessary medical procedures. The consistency of REDMOD’s output was further bolstered by repeat scans from the same patients, which yielded 90 to 92% concordance in detecting early malignant signatures months apart, illustrating the AI’s longitudinal reliability.

Perhaps most compelling is REDMOD’s performance relative to highly experienced radiologists. The AI achieved a sensitivity of 73% in detecting early-stage PDAC changes—nearly double the 39% sensitivity attributed to human experts. This gap widened dramatically for cases detected over two years before clinical diagnosis, with REDMOD maintaining a 68% accuracy while radiologist detection fell to only 23%. These findings challenge the current clinical reliance on human interpretation alone and advocate for AI integration to capture otherwise invisible radiological cues.

Despite these promising results, the lead researchers cautiously note that further validation in prospective, high-risk patient groups remains imperative before widespread clinical adoption. Patients exhibiting symptoms such as unexpected weight loss or recent-onset diabetes—conditions often associated with increased PDAC risk—may benefit most from such AI surveillance. Moreover, while this study benefitted from multi-institutional data enhancing its generalizability, the participant demographics lacked ethnic diversity, signaling an area for expansion in future research.

At its core, the REDMOD framework represents a convergence of advanced computational imaging analysis and clinical oncology. The system’s fully automated design eliminates the bottleneck of manual image segmentation, accelerating processing and reducing inter-operator variability. Beyond pancreatic cancer, such methodologies herald a new era of radiological precision medicine, wherein hidden oncologic processes can be unmasked well before they manifest clinically or morphologically to the human eye.

The implications of this research extend into health economics and patient quality of life. Modeling indicates that increasing early-stage, localized PDAC detection from 10% to 50% could more than double survival rates, illustrating the profound influence of diagnostic timing. In a disease where late diagnosis is the norm and effective treatment options are limited, the ability to non-invasively detect cancer over a year in advance transforms the clinical landscape, offering hope where few options previously existed.

In summary, REDMOD embodies a significant leap toward proactive pancreatic cancer detection. By unveiling the “invisible” textures of early cellular malignant transformation within routine CT scans, it empowers clinicians with unprecedented foresight. Although prospective trials and validation in diverse populations are essential next steps, this research lays the foundation for AI-enhanced diagnostic pathways that could save countless lives and fundamentally change the prognosis of a devastating cancer.

Subject of Research: People

Article Title: Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability

News Publication Date: 28-Apr-2026

Web References: 10.1136/gutjnl-2025-337266

Keywords

Pancreatic cancer, Artificial intelligence, Imaging, Radiology, Early detection, Pancreatic ductal adenocarcinoma, Radiomics, Computed tomography, Automated segmentation, Medical imaging analysis

Current screening methods for pancreatic cancer, while informative, often fall short when it comes to early detection. Traditional biomarkers, such as the carbohydrate antigen 19-9 (CA 19-9), are valuable for prognosis but lack the sensitivity required for identifying pancreatic cancer in its incipient stages. PAC-MANN fills this crucial gap by providing a tool that can pinpoint cancer-related activity in the bloodstream, thereby facilitating earlier diagnosis and optimizing treatment outcomes. The significance of this breakthrough is amplified by the fact that early detection is typically correlated with a more favorable prognosis, making it imperative for the medical field to adopt more sensitive screening methodologies.

Dr. Jared Fischer, a key scientist at the OHSU Knight Cancer Institute’s Cancer Early Detection Advanced Research Center (CEDAR), emphasizes the critical need for such a test. He states, “The problem with pancreatic cancer is that we often catch it too late.” Fischer and his colleagues have dedicated their research efforts to creating a more robust and user-friendly method for detecting pancreatic cancer, focusing on the practicality and accessibility of the PAC-MANN test. This endeavor aims to empower clinicians with tools that offer timely insights into patient health, particularly for those at an elevated risk for this devastating disease.

The development process for PAC-MANN involved analyzing blood samples from a diverse cohort of 350 patients, who approximately ranged from those diagnosed with pancreatic cancer, to those identified as high-risk candidates, as well as a control group. The researchers meticulously targeted specific proteins, particularly proteases, which exhibit increased activity in the presence of PDAC. This understanding enabled them to refine the test to recognize the protein markers associated with pancreatic cancer, thereby paving the way for a reliable and efficient diagnostic tool that works outside the confines of specialized laboratories.

In clinical evaluations, the PAC-MANN test demonstrated an impressive ability to distinguish between patients with pancreatic cancer and those without—achieving accuracy rates of 98%. This capability signifies not only a potential paradigm shift in diagnostic procedures but also a means to enhance patient monitoring throughout their treatment regimens, offering real-time adjustments based on protease activity levels. Such responsiveness allows clinicians to tailor therapeutic strategies that align with an individual patient’s specific needs, fundamentally transforming personalized medicine in oncology.

Research findings indicate that the PAC-MANN test doesn’t merely excel at initial detection; it also holds promise in tracking treatment efficacy over the course of a patient’s therapy. Following surgical interventions, a decrease in protease activity was observed, suggesting that this testing method could render critical insights into how well a patient’s treatment is progressing. As Dr. Fischer highlights, this capability to assess response in real time could contribute significantly to improving clinical decision-making and optimizing patient outcomes.

The accessibility of the PAC-MANN test is a notable aspect of its design. Unlike traditional methods, which often necessitate larger volumes of blood and complex procedures, PAC-MANN requires only 8 microliters of blood, rendering it a less invasive approach for screening potential pancreatic cancer cases. The promise of rapid results—within approximately 45 minutes—and the astonishingly low cost of less than a penny per sample enhances its appeal for widespread clinical adoption, particularly in underserved communities that often lack access to traditional testing modalities.

Looking ahead, there are plans for additional clinical trials, specifically tailored towards patients at high risk for developing pancreatic cancer. These investigator-initiated trials are grounded in a collaborative effort involving the OHSU Knight Cancer Institute and CEDAR, reflecting a commitment to validating the efficacy of the PAC-MANN test in real-world settings. If successful, these trials will further establish the test’s utility and effectiveness, potentially integrating PAC-MANN into routine clinical practice for pancreatic cancer screening and management.

Dr. Montoya Mira, a research engineer and co-author of the study, notes the aim of developing an economically viable and efficient testing method that transcends the limitations of existing practices. He envisions a future where PAC-MANN can be utilized not only in urban hospitals but also in rural settings where logistical constraints could jeopardize early cancer detection. This vision encapsulates the core mission of the researchers—to democratize access to essential healthcare tools that can save lives and improve outcomes for patients facing pancreatic cancer.

In summary, the PAC-MANN test represents a landmark achievement in the ongoing battle against pancreatic cancer. By enabling earlier detection and facilitating the monitoring of treatment efficacy, this innovative blood test could fundamentally change the landscape of care for patients suffering from one of the most lethal cancers. The potential impact of such a tool echoes through the echoes of the oncology community, providing a glimmer of hope in an often grim scenario characterized by late-stage diagnoses and limited therapeutic options. As the research moves forward, the excitement builds around the possibility of a future where pancreatic cancer is caught in its earliest stages, significantly enhancing survival chances for those affected.

Subject of Research: Human tissue samples
Article Title: PAC-MANN in the pancreas: Blood test for early pancreatic cancer shows promise in trial
News Publication Date: 12-Feb-2025
Web References: http://dx.doi.org/10.1126/scitranslmed.adq3110
References:
Image Credits: OHSU/Christine Torres Hicks

Keywords: Pancreatic cancer, blood test, protease activity, early detection, oncology, PAC-MANN, OHSU, treatment monitoring